Massachusetts Financial Services Co. MA Purchases Shares of 32,449 Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Massachusetts Financial Services Co. MA acquired a new stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 32,449 shares of the company’s stock, valued at approximately $1,253,000. Massachusetts Financial Services Co. MA owned 0.05% of Protagonist Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. State Street Corp lifted its holdings in Protagonist Therapeutics by 52.9% during the 3rd quarter. State Street Corp now owns 3,183,542 shares of the company’s stock valued at $143,259,000 after purchasing an additional 1,101,218 shares during the last quarter. Wellington Management Group LLP raised its stake in shares of Protagonist Therapeutics by 3,025.4% in the fourth quarter. Wellington Management Group LLP now owns 940,077 shares of the company’s stock valued at $36,287,000 after acquiring an additional 909,998 shares during the last quarter. American Century Companies Inc. boosted its holdings in shares of Protagonist Therapeutics by 61.5% in the 4th quarter. American Century Companies Inc. now owns 928,286 shares of the company’s stock worth $35,832,000 after acquiring an additional 353,511 shares in the last quarter. Principal Financial Group Inc. grew its position in Protagonist Therapeutics by 3,099.4% during the 3rd quarter. Principal Financial Group Inc. now owns 320,832 shares of the company’s stock worth $14,437,000 after acquiring an additional 310,804 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in Protagonist Therapeutics during the 4th quarter valued at $11,708,000. Institutional investors and hedge funds own 98.63% of the company’s stock.

Insider Activity

In other Protagonist Therapeutics news, insider Arturo Md Molina sold 30,514 shares of the company’s stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $55.74, for a total value of $1,700,850.36. Following the completion of the sale, the insider now owns 83,892 shares of the company’s stock, valued at approximately $4,676,140.08. This represents a 26.67 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director William D. Waddill sold 4,000 shares of the stock in a transaction on Monday, March 17th. The stock was sold at an average price of $54.25, for a total transaction of $217,000.00. Following the completion of the sale, the director now owns 13,130 shares in the company, valued at approximately $712,302.50. This trade represents a 23.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 64,776 shares of company stock valued at $3,585,010 in the last ninety days. 5.40% of the stock is owned by insiders.

Protagonist Therapeutics Stock Performance

PTGX opened at $41.67 on Wednesday. The company has a fifty day moving average price of $43.72 and a two-hundred day moving average price of $42.84. The firm has a market capitalization of $2.56 billion, a PE ratio of 15.67 and a beta of 2.30. Protagonist Therapeutics, Inc. has a 52 week low of $24.22 and a 52 week high of $60.60.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its quarterly earnings data on Friday, February 21st. The company reported $1.98 EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $2.07. Protagonist Therapeutics had a return on equity of 34.68% and a net margin of 52.76%. The business had revenue of $170.64 million during the quarter, compared to analysts’ expectations of $56.65 million. Equities analysts forecast that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have recently commented on PTGX. JMP Securities restated a “market outperform” rating and set a $58.00 target price on shares of Protagonist Therapeutics in a report on Friday, February 7th. The Goldman Sachs Group decreased their price objective on shares of Protagonist Therapeutics from $43.00 to $38.00 and set a “neutral” rating on the stock in a report on Monday, February 24th. JPMorgan Chase & Co. boosted their target price on shares of Protagonist Therapeutics from $53.00 to $57.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 4th. BTIG Research set a $73.00 price target on shares of Protagonist Therapeutics in a research note on Monday, March 3rd. Finally, BMO Capital Markets boosted their price objective on shares of Protagonist Therapeutics from $62.00 to $72.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 11th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $62.56.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.